<div><div><h2>Buy Natco Pharma; target of Rs 930: Anand Rathi</h2></div><div>"anand rathi's research report on natco pharmafocus on oncology new entrant in cnd division in domestic formulations. in domestic formulations natco is focusing on oncology and entered cnd (cardiology diabetology) in early 2017 where its focus is on niche molecules with high entry barriers. it enjoys a strong brand in oncology (six brands with more than `100m revenue) and hepatitis c. within oncology it offers a range of brands catering to various oncological diseases of the breast brain bone lung and ovaries. in cnd the launches could be either at-risk settlement with innovators for launches prior to day-1 or complex limited-competition ones (argatroban). overall we expect a ~16% cagr in revenue over fy18-21 with a targeted launch of 8-10 products a year.outlookwe retain our buy recommendation and roll forward our price target to fy21 at a revised target of `930 (earlier `937) based on a sum-of-parts method. we value the base business at `757 based on 20x fy21e earnings and the para-iv opportunity at `173.for all recommendations report click heredisclaimer: the views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own and not that of the website or its management. moneycontrol.com advises users to check with certified experts before taking any investment decisions.natco pharma_161118"</div></div>